Source: BioPortfolio

ImmBio: ImmBio Selected for an Oral Presentation at the 10th International Symposium on Pneumococci & Pneumococcal Diseases ISPPD10

Data from PnuBioVax Pneumococcal Vaccine Phase I Clinical Trial to be Presented Cambridge UK 23 June 2016 - ImmunoBiology Ltd "ImmBio" or the Company a biopharmaceutical company developing next generation antiinfec...

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100



ImmBio is a Private company. ImmBio generates $1M in revenue per employee